IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as firs... von Cappuzzo, F., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H.J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., Zer, A., Reinmuth, N., Sadiq, A., Archer, V., Ochi Lohmann, T., Wang, L., Kowanetz, M., Lin, W., Sandler, A., West, H.

Volltext

LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as... von Cappuzzo, F, McCleod, M, Hussein, M, Morabito, A, Rittmeyer, A, Conter, H J, Kopp, H-G, Daniel, D, McCune, S, Mekhail, T, Zer, A, Reinmuth, N, Sadiq, A, Archer, V, Ochi Lohmann, T, Wang, L, Kowanetz, M, Lin, W, Sandler, A, West, H

Volltext

BAYESIAN DOSIMETRY II: CREDIBILITY INTERVALS FOR RADIATION DOSE von MADRUGA, MARIA REGINA, OCHI-LOHMANN, TANIA HELENA, OKAZAKI, KAYO, DE BRAGANÇA PEREIRA, CARLOS ALBERTO, RABELLO-GAY, MARIA NAZARETH

Volltext

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lu... von West, Howard, McCleod, Michael, Hussein, Maen, Morabito, Alessandro, Rittmeyer, Achim, Conter, Henry J, Kopp, Hans-Georg, Daniel, Davey, McCune, Steven, Mekhail, Tarek, Zer, Alona, Reinmuth, Niels, Sadiq, Ahad, Sandler, Alan, Lin, Wei, Ochi Lohmann, Tania, Archer, Venice, Wang, Lijia, Kowanetz, Marcin, Cappuzzo, Federico

Volltext

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer von Wu, Yi-Long, Dziadziuszko, Rafal, Ahn, Jin Seok, Barlesi, Fabrice, Nishio, Makoto, Lee, Dae Ho, Lee, Jong-Seok, Zhong, Wenzhao, Horinouchi, Hidehito, Mao, Weimin, Hochmair, Maximilian, de Marinis, Filippo, Migliorino, M. Rita, Bondarenko, Igor, Lu, Shun, Wang, Qun, Ochi Lohmann, Tania, Xu, Tingting, Cardona, Andres, Ruf, Thorsten, Noe, Johannes, Solomon, Benjamin J.

Volltext

Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies von Bugarski-Kirola, Dragana, Blaettler, Thomas, Arango, Celso, Fleischhacker, Wolfgang W, Garibaldi, George, Wang, Alice, Dixon, Mark, Bressan, Rodrigo A, Nasrallah, Henry, Lawrie, Stephen, Napieralski, Julie, Ochi-Lohmann, Tania, Reid, Carol, Marder, Stephen R

Volltext

Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab a... von West, Howard L., McCleod, Michael, Hussein, Maen, Morabito, Alessandro, Rittmeyer, Achim, Conter, Henry J., Kopp, Hans-Georg, Daniel, Davey, McCune, Steven, Mekhail, Tarek, Zer, Alona, Reinmuth, Niels, Sadiq, Ahad, Archer, Venice, Lohmann, Tania Ochi, Jessop, Helen, Wang, Lijia, Kowanetz, Marcin, Sandler, Alan, Cappuzzo, Federico

Volltext

Efficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — R... von Arango, Celso, Nasrallah, Henry, Lawrie, Stephen, Lohmann, Tania Ochi, Zhu, Jon Luca, Garibaldi, George, Wang, Alice, Bugarski-Kirola, Dragana

Volltext

Mice presenting skeletal muscle hypertrophic phenotype driven by mIGF‐1 over‐expression have improved carbohydrate metabolism and insulin sensitivity von Christoffolete, Marcelo Augusto, de Oliveira‐Costa, Monique, Okamoto, Maristela M., Turri, Antonio, Lohmann, Tania Ochi, Ribeiro, Miriam Oliveira, Machado, Ubiratan Fabres, Musarò, Antonio, Moriscot, Anselmo Sigari

Volltext